Harish Govindaraja Setty Chinnari

Title: Innovator Spotlight: Harish Govindaraja Setty Chinnari

Introduction

Harish Govindaraja Setty Chinnari is a distinguished inventor based in Hyderabad, Telangana, India. With a robust portfolio of five patents, he has made significant contributions to the pharmaceutical industry, particularly in the development of stable and effective injectable solutions.

Latest Patents

Among his notable inventions are two key patents focused on injectable pharmaceutical compositions. The first patent pertains to stable pharmaceutical compositions of bendamustine, offering ready-to-dilute (RTD) or ready-to-use (RTU) options that facilitate intravenous administration. These formulations are designed to be antioxidant-free and include essential components such as pharmaceutically acceptable solvents and stabilizers. The second patent discloses stable injectable compositions of glucagon, which are also designed for multiple modes of administration. This invention ensures that the injectable solutions are stable, ready-to-use, and contain specific stabilizing agents and sugars to enhance efficacy.

Career Highlights

Harish operates at Slayback Pharma LLC, a company known for its commitment to developing innovative pharmaceutical products. His research and innovations are critical in enhancing the quality and stability of injectable medicines, which is essential for patient safety and treatment efficacy.

Collaborations

During his tenure, Harish has collaborated with several esteemed colleagues, including Somashekhar Battini and Sumitra Ashokkumar Pillai. These partnerships have fostered an environment of innovation, contributing to the successful development of pharmaceutical compositions that meet the needs of healthcare providers and patients alike.

Conclusion

Harish Govindaraja Setty Chinnari exemplifies the spirit of innovation in the pharmaceutical sector. Through his patents and collaborative efforts, he is helping to shape the future of injectable therapies, ensuring that they are both effective and safe for patient use. His work at Slayback Pharma LLC continues to have a significant impact on the field of pharmaceuticals.